Comparison of Five Treatments in Patients With Plantar Warts

NCT ID: NCT01059110

Last Updated: 2017-01-11

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE4
• Total Enrollment: 358 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-02-28
• Study Completion Date: 2016-12-31

Brief Summary

The principal objective of the study is to compare 5 usual strategies in the management of plantar warts which did not cure after 5 weeks of a salicylate ointment given just prior the trial. The trial will include immunocompetent patients coming from the community and should help the office-based dermatologists and hospital in the decision-making therapeutic process.

Detailed Description

Four and a half million individuals in France have warts (SOFRES poll 2002). Notably, plantar warts are considered to be the most common reason for consulting a private practitioner, despite the absence of robust epidemiological data. Although benign, plantar warts are associated with a certain degree of morbidity: pain, difficulty walking, and intra- and interindividual contagion. Despite the frequency of plantar warts and patients high expectations for their treatments, which are numerous for immunocompetent patients, those remedies have only been evaluated in undeniably inadequate ways. Patient demand for therapy is strong, with those affected going from one physician to another, in the search for the "good treatment". For all the reasons evoked in the context of skin diseases, healing warts can indeed represent a public health objective.

One of the difficulties of evaluating treatments is the frequency of spontaneous complete remissions (natural history) and/or under placebo, assessed at 30% [range: 0-73%] in a short-term trial (10 weeks). In addition, professionals experiences support frequent relapses that have been very poorly evaluated in therapeutic trials.

Keratolytic treatment, usually salicylated petroleum jelly, is the standard therapy according to the Cochrane Review. In practice, this therapy usually combines manual shaving, done by the patient him/herself or the physician. Supplementing this basic therapy with a physical (standard cryotherapy), chemical (5-fluorouracil; Efudix®) or immunological adjunct (imiquimod; Aldara®), to achieve the desired effect of increasing the frequency and/or rapidity of complete cure, has never been examined in a large randomized-controlled trial.

A population comprised of patients with warts still "resistant" after 5 weeks of keratolytic therapy with 50% salicylic acid (PommadeM.O Cochon®) followed by a 1-week washout was deliberately retained because it is this precise setting that poses therapeutic difficulties in routine practice. The 1-week washout will allow the skin to heal a little and facilitate the diagnosis of failures; and, moreover, the strategy of pretreatment with scraping would not be unduly weakened.

Conditions

Plantar Warts

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Salicylate ointment

Salicylate ointment under occlusion (pomade M.O Cochon®)

Group Type: EXPERIMENTAL

Salicylate ointment

Intervention Type: DRUG

cream, one application every night, for 90 days

Imiquimod

Imiquimod : Aldara®

Group Type: EXPERIMENTAL

Imiquimod

Intervention Type: DRUG

cream, one dose of 250 mg, one application 3 times a week during 12 hours, for 90 days

5-fluoro-uracil

5-fluoro-uracil cream : Efudix®

Group Type: EXPERIMENTAL

5-Fluoro-Uracil

Intervention Type: DRUG

cream, one application every night, during 12 hours, for 90 days

Cryotherapy

liquid nitrogen : Cryotherapy

Group Type: EXPERIMENTAL

Cryotherapy

Intervention Type: DRUG

2 cycles of 5 seconds after obtention of halo of white

Interventions

Salicylate ointment

cream, one application every night, for 90 days

Intervention Type: DRUG

Imiquimod

cream, one dose of 250 mg, one application 3 times a week during 12 hours, for 90 days

Intervention Type: DRUG

5-Fluoro-Uracil

cream, one application every night, during 12 hours, for 90 days

Intervention Type: DRUG

Cryotherapy

2 cycles of 5 seconds after obtention of halo of white

Intervention Type: DRUG

Other Intervention Names

pommade M.O Cochon®; Aldara® 5%; Efudix® 5%; Liquid nitrogen

Eligibility Criteria

Inclusion Criteria

• Male or female patient aged 18 years or more.
• Clinical evaluation
• Number of warts lower than 10 on the 2 feet and total diameter of warts lower than 10 cm, whether previously treated or not
• In treated patients, all potentially active treatment on warts since at least one month should be stopped.
• Effective contraception for women of childbearing age
• Immunocompetent patients
• Patient with one or more warts on soles and board feet.

• MYRMECIE : rounded warts, deep, covered with a stratum corneum more or less thick; after stripping, appear black points, very specific; often painful to pressure. They are lonely, single or not. They could regroup galley thick. The stripping can them to individualize.
• Mosaic : plate small warts, superficial, often sitting on the heel or Forefoot. Little painful, they are often ignored by the patients when they appear
• Patient affiliated to the French social security.

Exclusion Criteria

• Patient suspected to be immunocompromised
• Patient aged under 18 years
• Patient refusing to sign the consent
• Pregnant or lactating women
• Plantar calluses
• Known hypersensitivity to imiquimod (Aldara®) or any excipients of the cream (isostearic acid, benzyl alcohol, cetyl alcohol, stearyl alcohol, paraffin, polysorbate 60, sorbitan stearate, glycerol, methyl hydroxybenzoate, propyl hydroxybenzoate, xanthan gum, purified water)
• Known hypersensitivity to 5 fluoro-uracil (Efudix®) or any excipients of gel (stearyl alcohol, Vaseline, polysorbate 60, propyleneglycol, purified water - conservatives: METHYL PARAHYDROXYBENZOATE, PROPYL PARAHYDROXYBENZOATE)
• Contra-indication to Pomade M.O Cochon® (Known allergy to any components)
• Known hypersensitivity to Blenderm®
• Extra plantar concomitant warts (to exclude risk of endogenous recontamination by an extra plantar site)
• Plantar hyperhidrosis making impossible adhesion of plaster.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Society of Dermatology and venerology

UNKNOWN

Sponsor Role: collaborator

Assistance Publique - Hôpitaux de Paris

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Olivier CHOSIDOW, MD,PhD

Role: PRINCIPAL_INVESTIGATOR

Assistance Publique - Hôpitaux de Paris

Locations

Medical center

Athis-Mons, , France

Countries

France

References

Chanal J, Aubin F, Penso-Assathiany D, Buffiere I, Makhlouf W, Perriere C, Bocquet H, Aubin A, Farcet Y, Ludmann C, Duboz A, Marco-Bonnet J, Maury C, Tremeau-Martinage C, Hubert-Asso AM, Coustou D, Heudes AM, Kemula M, Beylot-Barry M, Tetart F, Eche-Dejoie A, Duvochel AM, Baspeyras M, Amici JM, Toussaint H, Neculaita L, Mboup B, Pizzi N, Jouis V, Vacher Y, Pretet JL, Vicaut E, Chosidow O. A multicentre pragmatic randomized controlled trial comparing 50% salicylic acid, liquid nitrogen, 5% 5-fluorouracil cream, and 5% imiquimod cream in previously treated plantar warts. The VRAIE (VeRrues plAntaIres en villE) study. Ann Dermatol Venereol. 2025 Sep;152(3):103406. doi: 10.1016/j.annder.2025.103406. Epub 2025 Jul 30.

Reference Type: DERIVED

PMID: 40743833 (View on PubMed)

Other Identifiers

P070701

Identifier Type: -

Identifier Source: org_study_id